Morgan Lewis is adding to its global life sciences team with the hiring of partner Suzanne Filippi, who has almost two decades of experience in the biopharmaceutical and technology sectors, including strategic roles both in-house and in private practice. She is resident in the Boston office and arrives from the life sciences group at Hogan Lovells. Suzanne’s practice focuses on complex collaboration/licensing transactions, strategic alliances, clinical and commercial supply transactions, build-to-buy transactions, public and private mergers and acquisitions, venture capital, and joint ventures.
“Suzanne’s sophisticated biotech in-house and law firm experience gives her the collaborative and business savvy edge our clients depend on when pursuing new strategic business opportunities,” said firm chair Jami McKeon. “Our global life sciences transactions team is reinforced by Suzanne’s arrival as we navigate clients around the globe through remaining COVID-related issues and the implications of the American Rescue Plan Act.”
“In a time when life sciences companies are seeing a proliferation of complex licensing and collaboration transactions as well as sustained M&A activity, clients are seeking counsel such as Suzanne with her in-depth knowledge of the industry,” said Alan Leeds, leader of Morgan Lewis’s life sciences transactions practice and co-leader of the firm’s life sciences industry initiative. “Clients value her entrepreneurial approach and seasoned counsel on a vast range of issues that are critical to their businesses.”